Takeda Pharmaceutical Company (TKDA) Financial Statements

4 Followers

Takeda Pharmaceutical Company Financial Overview

Takeda Pharmaceutical Company's market cap is currently €48.76B. The company's EPS TTM is €57.57; its P/E ratio is 129.50; Takeda Pharmaceutical Company is scheduled to report earnings on July 30, 2026, and the estimated EPS forecast is €0.12. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
Income Statement
Total Revenue	¥ 4.78T	¥ 4.58T	¥ 4.26T	¥ 4.03T	¥ 3.57T
Gross Profit	¥ 2.44T	¥ 3.00T	¥ 2.83T	¥ 2.78T	¥ 2.46T
Operating Income	¥ 573.04B	¥ 342.59B	¥ 214.07B	¥ 490.50B	¥ 460.84B
EBITDA	¥ 1.42T	¥ 1.21T	¥ 1.14T	¥ 1.28T	¥ 1.18T
Net Income	¥ 203.33B	¥ 107.93B	¥ 144.07B	¥ 317.02B	¥ 230.06B
Balance Sheet
Cash & Short-Term Investments	¥ 597.63B	¥ 405.59B	¥ 472.89B	¥ 553.70B	¥ 875.00B
Total Assets	¥ 15.52T	¥ 14.25T	¥ 15.11T	¥ 13.96T	¥ 13.18T
Total Debt	¥ 4.90T	¥ 4.52T	¥ 4.84T	¥ 4.38T	¥ 4.35T
Net Debt	¥ 4.31T	¥ 4.13T	¥ 4.39T	¥ 3.85T	¥ 3.50T
Total Liabilities	¥ 7.71T	¥ 7.31T	¥ 7.83T	¥ 7.60T	¥ 7.49T
Stockholders' Equity	¥ 7.81T	¥ 6.94T	¥ 7.27T	¥ 6.35T	¥ 5.68T
Cash Flow
Free Cash Flow	¥ 626.77B	¥ 677.56B	¥ 235.61B	¥ 343.47B	¥ 937.07B
Operating Cash Flow	¥ 1.04T	¥ 1.06T	¥ 716.34B	¥ 977.16B	¥ 1.12T
Investing Cash Flow	¥ -369.14B	¥ -367.06B	¥ -463.86B	¥ -607.10B	¥ -198.13B
Financing Cash Flow	¥ -496.82B	¥ -751.42B	¥ -354.42B	¥ -709.15B	¥ -1.07T

Currency in JPY

Takeda Pharmaceutical Company Earnings and Revenue History

Income Statement >

Takeda Pharmaceutical Company Debt to Assets

Balance Sheet >

Takeda Pharmaceutical Company Cash Flow

Cash Flow >

Takeda Pharmaceutical Company Forecast EPS vs Actual EPS

Earnings >